Prevnar

Pfizer reported largely unchanged quarterly revenue as declining COVID-19 products and weaker Prevnar vaccine sales offset growth in oncology, cardiovascular and migraine treatments. Management raised its annual revenue and adjusted earnings forecasts, but research expenditure and continuing product competition remain important challenges.